The APL paradigm and the "co-clinical trial" project

Cancer Discovery

Volumn 1, Issue 2, 2011, Pages 108-116

  Nardella, Caterina ^a,b   Lunardi, Andrea ^a   Patnaik, Akash ^a,c   Cantley, Lewis C ^a,c   Pandolfi, Pier Paolo ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Division of Genetics   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CATHEPSIN G; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; NEW DRUG; PHENYL BUTYRATE; RETINOIC ACID; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL; ARTICLE; BIOINFORMATICS; CANCER COMBINATION CHEMOTHERAPY; CELL HETEROGENEITY; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION; DATA ANALYSIS; DATA MINING; DRUG SCREENING; FUSION GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETICS; HOSPITAL; HUMAN; IMAGING SYSTEM; INFORMATION PROCESSING; MOUSE; MUTATION; NONHUMAN; ONCOGENE; PATHOLOGY; PHARMACY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROMYELOCYTIC LEUKEMIA; THERAPY EFFECT; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION PROCESS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MUTATION;

EID: 84859440747     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0061     Document Type: Article

References (17)

1. Nasr R, Guillemin MC, Ferhi O, Soilihi H, Peres L, Berthier C, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008;14:1333-42.
2. Rowley JD. Chromosomal patterns in myelocytic leukemia. N Engl J Med 1973;289:220-1.
3. Pandolfi PP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 1991;6:1285-92.
4. Piazza F, Gurrieri C, Pandolfi PP. The theory of APL. Oncogene 2001;20:7216-22.
5. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, et al. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A 1997;94:5302-7.
6. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ. Altered myeloid development and acute leukemia in transgenic mice expressing PMLRAR alpha under control of cathepsin G regulatory sequences. Blood 1997;89:376-87.
7. Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci PG, et al. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997;94:2551-6.
8. He LZ, Bhaumik M, Tribioli C, Rego EM, Ivins S, Zelent A, et al. Two critical hits for promyelocytic leukemia. Mol Cell 2000;6:1131-41.
9. Rego EM, Ruggero D, Tribioli C, Cattoretti G, Kogan S, Redner RL, et al. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene 2006;25:1974-9.
10. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 1998;18:126-35.
11. Rego EM, He LZ, Warrell RP, Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A 2000;97:10173-8.
12. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-52.
13. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/ RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998;90:124-33.
14. Nasr R, de The H. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int J Hematol 2010;91:742-7.
15. Pandolfi PP. Transcription therapy for cancer. Oncogene 2001;20:3116-27.
16. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP, Jr, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001;108:1321-30.
17. Warrell RP, Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998;90:1621-5.